RU2005121672A - Способ ингибирования в условиях in vitro функции и/или пролиферации клетки, экспрессирующей тирозинкиназу janus 3 (jak3) (варианты), способ тестирования соединений in vitro в качестве перспективных терапевтических иммунодепрессантов и идентификации in vitro нового иммунодепрессивного лекарственного средства (варианты), стериозомер и фармацевтическая композиция на его основе, применение вышеуказанных объектов в качестве средства подавления нежелательной функции клетки у млекопитающего - Google Patents
Способ ингибирования в условиях in vitro функции и/или пролиферации клетки, экспрессирующей тирозинкиназу janus 3 (jak3) (варианты), способ тестирования соединений in vitro в качестве перспективных терапевтических иммунодепрессантов и идентификации in vitro нового иммунодепрессивного лекарственного средства (варианты), стериозомер и фармацевтическая композиция на его основе, применение вышеуказанных объектов в качестве средства подавления нежелательной функции клетки у млекопитающего Download PDFInfo
- Publication number
- RU2005121672A RU2005121672A RU2005121672/15A RU2005121672A RU2005121672A RU 2005121672 A RU2005121672 A RU 2005121672A RU 2005121672/15 A RU2005121672/15 A RU 2005121672/15A RU 2005121672 A RU2005121672 A RU 2005121672A RU 2005121672 A RU2005121672 A RU 2005121672A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- cell
- jak3
- vitro
- activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 39
- 238000000034 method Methods 0.000 title claims 16
- 230000002401 inhibitory effect Effects 0.000 title claims 11
- 230000035755 proliferation Effects 0.000 title claims 11
- 238000000338 in vitro Methods 0.000 title claims 9
- 241000124008 Mammalia Species 0.000 title claims 8
- 239000003018 immunosuppressive agent Substances 0.000 title claims 8
- 238000012360 testing method Methods 0.000 title claims 8
- 230000006870 function Effects 0.000 title claims 5
- 229960003444 immunosuppressant agent Drugs 0.000 title claims 5
- 230000001225 therapeutic effect Effects 0.000 title claims 4
- 230000003915 cell function Effects 0.000 title claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 title 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 230000000694 effects Effects 0.000 claims 17
- 101150069380 JAK3 gene Proteins 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 13
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 12
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 claims 11
- 101150009057 JAK2 gene Proteins 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 230000005764 inhibitory process Effects 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 4
- 210000004698 lymphocyte Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 3
- 229930105110 Cyclosporin A Natural products 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 102000003946 Prolactin Human genes 0.000 claims 2
- 108010057464 Prolactin Proteins 0.000 claims 2
- 101150058731 STAT5A gene Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 229940097325 prolactin Drugs 0.000 claims 2
- 230000000284 resting effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000006470 autoimmune attack Effects 0.000 claims 1
- 230000006472 autoimmune response Effects 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
- C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
- C07C225/12—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43185102P | 2002-12-09 | 2002-12-09 | |
| US60/431,851 | 2002-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005121672A true RU2005121672A (ru) | 2005-11-20 |
Family
ID=32507812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005121672/15A RU2005121672A (ru) | 2002-12-09 | 2003-12-09 | Способ ингибирования в условиях in vitro функции и/или пролиферации клетки, экспрессирующей тирозинкиназу janus 3 (jak3) (варианты), способ тестирования соединений in vitro в качестве перспективных терапевтических иммунодепрессантов и идентификации in vitro нового иммунодепрессивного лекарственного средства (варианты), стериозомер и фармацевтическая композиция на его основе, применение вышеуказанных объектов в качестве средства подавления нежелательной функции клетки у млекопитающего |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7365096B2 (https=) |
| EP (1) | EP1578411A4 (https=) |
| JP (1) | JP2006514021A (https=) |
| KR (1) | KR20050084224A (https=) |
| CN (1) | CN1747729A (https=) |
| AU (1) | AU2003297740B2 (https=) |
| BR (1) | BR0317099A (https=) |
| CA (1) | CA2506432A1 (https=) |
| EC (1) | ECSP055843A (https=) |
| HU (1) | HUP0500844A2 (https=) |
| MX (1) | MXPA05006133A (https=) |
| NO (1) | NO20052497L (https=) |
| NZ (1) | NZ540427A (https=) |
| PL (1) | PL376844A1 (https=) |
| RU (1) | RU2005121672A (https=) |
| WO (1) | WO2004052359A1 (https=) |
| ZA (1) | ZA200504163B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7943800B2 (en) | 2003-03-28 | 2011-05-17 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
| WO2005012294A1 (en) | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| AU2005237254B2 (en) * | 2004-05-03 | 2010-02-04 | Novartis Ag | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor |
| JP5149001B2 (ja) | 2004-05-25 | 2013-02-20 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | 癌の処置におけるマイグラスタチンアナログ |
| US8188141B2 (en) | 2004-09-23 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Isomigrastatin analogs in the treatment of cancer |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| EP1883302A4 (en) * | 2005-05-03 | 2009-05-20 | Rigel Pharmaceuticals Inc | JAK KINASE HEMMER AND ITS USE |
| PL1940465T3 (pl) | 2005-10-26 | 2013-01-31 | Novartis Ag | Nowe zastosowanie przeciwciał anty-IL-1beta |
| NO20220050A1 (no) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| CN104873972A (zh) | 2007-05-29 | 2015-09-02 | 诺华股份有限公司 | 抗IL-1β治疗的新适应症 |
| JP2011515068A (ja) | 2007-11-08 | 2011-05-19 | ノバルティス アーゲー | 慢性／硬化性同種移植腎症に対する遺伝子発現シグネチャー |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| WO2011006119A2 (en) | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| US9018006B2 (en) | 2010-07-23 | 2015-04-28 | The University Of Toledo | Stable Tregs and related materials and methods |
| KR20140025530A (ko) | 2011-06-27 | 2014-03-04 | 노파르티스 아게 | 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염 |
| ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| CN103987699A (zh) | 2011-10-21 | 2014-08-13 | 诺华股份有限公司 | 作为pi3k调节剂的喹唑啉衍生物 |
| US20140348848A1 (en) | 2011-12-02 | 2014-11-27 | Dhananjay Kaul | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| EP2790705B1 (en) | 2011-12-15 | 2017-12-06 | Novartis AG | Use of inhibitors of the activity or function of pi3k |
| JO3398B1 (ar) | 2011-12-22 | 2019-10-20 | Novartis Ag | مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي |
| EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
| WO2013148638A2 (en) * | 2012-03-26 | 2013-10-03 | Ep Pharma, Inc. | Compositions and methods related to inhibitors of jak kinase |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| WO2015179773A1 (en) | 2014-05-22 | 2015-11-26 | The Scripps Research Institute | Tissue molecular signatures of kidney transplant rejections |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US9862711B2 (en) | 2014-04-24 | 2018-01-09 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US10443100B2 (en) | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| US11104951B2 (en) | 2014-05-22 | 2021-08-31 | The Scripps Research Institute | Molecular signatures for distinguishing liver transplant rejections or injuries |
| CN104090115B (zh) * | 2014-07-10 | 2016-01-13 | 上海益诺思生物技术有限公司 | 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法 |
| KR102737185B1 (ko) | 2018-01-20 | 2024-12-05 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 아미노피리미딘 화합물 및 이의 사용 방법 |
| WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
| CN113840821A (zh) | 2019-05-23 | 2021-12-24 | 诺华股份有限公司 | Btk抑制剂的晶型 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA712187A (en) * | 1965-06-22 | J. C. Buisson Paul | 2-(2'-oxo-1'-cyclododecyl) acetic acid, the salts thereof, and process of preparing same | |
| FR1466205A (fr) * | 1960-04-01 | 1967-01-20 | Chimie Atomistique | Acide 1-cétocyclododécyl-2-acétique, ses sels et leur procédé de préparation |
| AU566673B2 (en) | 1983-09-15 | 1987-10-29 | F. Hoffmann-La Roche Ag | Phenethylamine derivatives |
| US6136595A (en) * | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
| KR20010089171A (ko) | 1998-08-21 | 2001-09-29 | 추후제출 | 퀴나졸린 유도체 |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| CA2392554A1 (en) * | 1999-11-30 | 2001-06-28 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| CA2326952A1 (en) | 2000-11-27 | 2002-05-27 | The Hospital For Sick Children | T cell protein tyrosine phosphatase |
-
2003
- 2003-12-09 CA CA002506432A patent/CA2506432A1/en not_active Abandoned
- 2003-12-09 HU HU0500844A patent/HUP0500844A2/hu unknown
- 2003-12-09 EP EP03796805A patent/EP1578411A4/en not_active Withdrawn
- 2003-12-09 US US10/731,769 patent/US7365096B2/en not_active Expired - Fee Related
- 2003-12-09 CN CNA2003801054687A patent/CN1747729A/zh active Pending
- 2003-12-09 JP JP2004559442A patent/JP2006514021A/ja active Pending
- 2003-12-09 BR BR0317099-3A patent/BR0317099A/pt not_active IP Right Cessation
- 2003-12-09 KR KR1020057010469A patent/KR20050084224A/ko not_active Ceased
- 2003-12-09 NZ NZ540427A patent/NZ540427A/en unknown
- 2003-12-09 AU AU2003297740A patent/AU2003297740B2/en not_active Ceased
- 2003-12-09 MX MXPA05006133A patent/MXPA05006133A/es unknown
- 2003-12-09 WO PCT/US2003/038993 patent/WO2004052359A1/en not_active Ceased
- 2003-12-09 RU RU2005121672/15A patent/RU2005121672A/ru not_active Application Discontinuation
- 2003-12-09 PL PL376844A patent/PL376844A1/pl not_active Application Discontinuation
-
2005
- 2005-05-23 ZA ZA200504163A patent/ZA200504163B/en unknown
- 2005-05-24 NO NO20052497A patent/NO20052497L/no not_active Application Discontinuation
- 2005-06-08 EC EC2005005843A patent/ECSP055843A/es unknown
-
2007
- 2007-11-05 US US11/935,147 patent/US7928062B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR0317099A (pt) | 2005-10-25 |
| NZ540427A (en) | 2008-04-30 |
| AU2003297740A1 (en) | 2004-06-30 |
| NO20052497D0 (no) | 2005-05-24 |
| NO20052497L (no) | 2005-09-02 |
| MXPA05006133A (es) | 2006-03-09 |
| CN1747729A (zh) | 2006-03-15 |
| JP2006514021A (ja) | 2006-04-27 |
| EP1578411A1 (en) | 2005-09-28 |
| EP1578411A4 (en) | 2007-05-02 |
| WO2004052359A1 (en) | 2004-06-24 |
| US7365096B2 (en) | 2008-04-29 |
| HUP0500844A2 (en) | 2007-08-28 |
| US7928062B2 (en) | 2011-04-19 |
| KR20050084224A (ko) | 2005-08-26 |
| AU2003297740A2 (en) | 2004-06-30 |
| ECSP055843A (es) | 2005-11-22 |
| CA2506432A1 (en) | 2004-06-24 |
| AU2003297740B2 (en) | 2008-09-11 |
| US20080167220A1 (en) | 2008-07-10 |
| ZA200504163B (en) | 2007-03-28 |
| US20050203177A1 (en) | 2005-09-15 |
| PL376844A1 (pl) | 2006-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005121672A (ru) | Способ ингибирования в условиях in vitro функции и/или пролиферации клетки, экспрессирующей тирозинкиназу janus 3 (jak3) (варианты), способ тестирования соединений in vitro в качестве перспективных терапевтических иммунодепрессантов и идентификации in vitro нового иммунодепрессивного лекарственного средства (варианты), стериозомер и фармацевтическая композиция на его основе, применение вышеуказанных объектов в качестве средства подавления нежелательной функции клетки у млекопитающего | |
| JP2006514021A5 (https=) | ||
| Joly et al. | Balloon injury and interleukin-1 beta induce nitric oxide synthase activity in rat carotid arteries. | |
| RU2220977C2 (ru) | Гетероциклы в качестве ингибиторов адгезии лейкоцитов и vla-4-антагонистов | |
| CN1635882B (zh) | 组合物在制备治疗听力丧失的药物中的用途 | |
| JPH08512048A (ja) | 例えばｎ−（３−オキシヘキサノイル）ホモセリンラクトンのような免疫抑制剤及び抗アレルギー性化合物 | |
| CA2832611C (en) | Methods for inhibiting allograft rejection | |
| JP2007538083A (ja) | 免疫炎症性障害の治療のための方法および試薬 | |
| He et al. | Inhibitory effects of glyceryl trinitrate on alpha‐adrenoceptor mediated contraction in the human internal mammary artery. | |
| Pomicter et al. | Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm | |
| EP1305047B1 (en) | Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection | |
| Mikkelsen et al. | Difference between aortic and renal vascular reactivity in cyclosporin A treated rats and the effect of cicletanine | |
| Didier et al. | Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers | |
| US20050025769A1 (en) | Method of suppressing ongoing acute allograft rejection | |
| Ma et al. | Is absorption profile of cyclosporine really important for effective immunosuppression? | |
| GB2185886A (en) | Immunosuppressant agents containing ergot derivatives | |
| Chen et al. | In vitro evaluation of the effect of a novel immunosuppressive agent, FTY720, on the function of feline neutrophils | |
| Bittiger et al. | A study of long-term effects of guanethidine on peripheral noradrenergic neurones of the rat | |
| CA2167842A1 (en) | Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes | |
| Azzola et al. | Inhibition of human lung fibroblast proliferation by immunosuppressive drugs-an in vitro model of the in vivo response? | |
| Fingerhut et al. | 3 Deazaadenosin prevents leukocyte evasion by suppression of adhesion molecule expression during acute cardiac allograft rejection | |
| Edwards et al. | Effects of a selective nitric oxide sythase-2 inhibitor in the prevention of acute cardiac allograft rejection | |
| Schweiger | Immunosuppressive therapy after cardiac transplantation | |
| Lefler et al. | Amelioration of hepatic ischemia/reperfusion injury using indolepropionic acid | |
| Rayat | A comparison of the immunosuppressive efficacy of Cyclosporine A (CsA) and Cyclosporine G (CsG) in vitro and in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081217 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20091210 |
|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20101122 |